I have been accumulating. And will keep adding. Trading is eerily similar to PDSB when it was a couple bucks. This company has so much upside for Nash & other indications. Great to see you onboard.
Hepa CRV431 Showing better results than MDGLwith less side effects at 28 days then MDGL Nash drug 1.8 Billion market cap..
HEPA AI powered platform saves the company time and money on their clinical trials: Multi-omics analyses – 25,000 data points per patient Identify biomarkers that predict response to CRV431 Optimize and de-risk clinical trials through patient matching to CRV431 – precision medicine.
The company said it has conducted nine individual animal studies of fibrosis and found consistent and statistically significant antifibrotic effects of CRV431 in every one of these studies. Antifibrotic activity has also been observed in previouslyreported studies conducted by an independent U.K. laboratory that studied explanted liver and lung tissues taken from human donors. Taken together, these animal and human tissue experiments give the company a "great deal of confidence" that CRV431 has beneficial antifibrotic effects that are expected to be borne out clinically.
News 
Market Data 
Discover 
